The development of a useful therapeutic treatment for COVID-19 would be substantial. As a low-market cap, non-vaccine COVID-19 therapeutic company currently undergoing a Phase 3 trial, Revive executives believe the company has strong growth potential as its Bucillamine trial meets safety and efficacy endpoints. Just wanted to repost the USA Today News for any new investors :-)